Cargando…

Sivelestat Attenuates Myocardial Reperfusion Injury during Brief Low Flow Postischemic Infusion

The neutrophil elastase inhibitor sivelestat (ONO-5046) possesses unknown mechanisms of cardioprotection when infused following global ischemia, even in the absence of neutrophils. Since myocardial ischemia-reperfusion injury is strongly associated with endothelial dysfunction and reactive oxygen sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Aune, Sverre E., Yeh, Steve T., Kuppusamy, Periannan, Kuppusamy, M. Lakshmi, Khan, Mahmood, Angelos, Mark G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674745/
https://www.ncbi.nlm.nih.gov/pubmed/23766850
http://dx.doi.org/10.1155/2013/279847
_version_ 1782272416388481024
author Aune, Sverre E.
Yeh, Steve T.
Kuppusamy, Periannan
Kuppusamy, M. Lakshmi
Khan, Mahmood
Angelos, Mark G.
author_facet Aune, Sverre E.
Yeh, Steve T.
Kuppusamy, Periannan
Kuppusamy, M. Lakshmi
Khan, Mahmood
Angelos, Mark G.
author_sort Aune, Sverre E.
collection PubMed
description The neutrophil elastase inhibitor sivelestat (ONO-5046) possesses unknown mechanisms of cardioprotection when infused following global ischemia, even in the absence of neutrophils. Since myocardial ischemia-reperfusion injury is strongly associated with endothelial dysfunction and reactive oxygen species (ROS) generation during reperfusion, we have tested the hypothesis that infusion of sivelestat during postischemic low flow would preserve endothelial and contractile function and reduce infarct size through an ROS-mediated mechanism. Isolated male rat hearts, subjected to global ischemia of 25 minutes, were reperfused with low flow with or without sivelestat followed by a full flow reperfusion. Hearts treated with sivelestat showed a significant improvement of LV contractile function and a reduction in infarct size. Infusion of L-NAME (nonspecific blocker of endothelial nitric oxide synthase (eNOS)) along with sivelestat during reperfusion reversed the preservation of contractile function and infarct size. In vitro EPR spin trapping experiments showed that sivelestat treatment decreased superoxide adduct formation in bovine aortic endothelial cells (BAECs) subjected to hypoxia-reoxygenation. Similarly, dihydroethidine (DHE) staining showed decreased superoxide production in LV sections from sivelestat-treated hearts. Taken together, these results indicate that sivelestat infusion during postischemic low flow reduces infarct size and preserves vasoreactivity in association with decreased ROS formation and the preservation of nitric oxide.
format Online
Article
Text
id pubmed-3674745
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36747452013-06-13 Sivelestat Attenuates Myocardial Reperfusion Injury during Brief Low Flow Postischemic Infusion Aune, Sverre E. Yeh, Steve T. Kuppusamy, Periannan Kuppusamy, M. Lakshmi Khan, Mahmood Angelos, Mark G. Oxid Med Cell Longev Research Article The neutrophil elastase inhibitor sivelestat (ONO-5046) possesses unknown mechanisms of cardioprotection when infused following global ischemia, even in the absence of neutrophils. Since myocardial ischemia-reperfusion injury is strongly associated with endothelial dysfunction and reactive oxygen species (ROS) generation during reperfusion, we have tested the hypothesis that infusion of sivelestat during postischemic low flow would preserve endothelial and contractile function and reduce infarct size through an ROS-mediated mechanism. Isolated male rat hearts, subjected to global ischemia of 25 minutes, were reperfused with low flow with or without sivelestat followed by a full flow reperfusion. Hearts treated with sivelestat showed a significant improvement of LV contractile function and a reduction in infarct size. Infusion of L-NAME (nonspecific blocker of endothelial nitric oxide synthase (eNOS)) along with sivelestat during reperfusion reversed the preservation of contractile function and infarct size. In vitro EPR spin trapping experiments showed that sivelestat treatment decreased superoxide adduct formation in bovine aortic endothelial cells (BAECs) subjected to hypoxia-reoxygenation. Similarly, dihydroethidine (DHE) staining showed decreased superoxide production in LV sections from sivelestat-treated hearts. Taken together, these results indicate that sivelestat infusion during postischemic low flow reduces infarct size and preserves vasoreactivity in association with decreased ROS formation and the preservation of nitric oxide. Hindawi Publishing Corporation 2013 2013-05-22 /pmc/articles/PMC3674745/ /pubmed/23766850 http://dx.doi.org/10.1155/2013/279847 Text en Copyright © 2013 Sverre E. Aune et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Aune, Sverre E.
Yeh, Steve T.
Kuppusamy, Periannan
Kuppusamy, M. Lakshmi
Khan, Mahmood
Angelos, Mark G.
Sivelestat Attenuates Myocardial Reperfusion Injury during Brief Low Flow Postischemic Infusion
title Sivelestat Attenuates Myocardial Reperfusion Injury during Brief Low Flow Postischemic Infusion
title_full Sivelestat Attenuates Myocardial Reperfusion Injury during Brief Low Flow Postischemic Infusion
title_fullStr Sivelestat Attenuates Myocardial Reperfusion Injury during Brief Low Flow Postischemic Infusion
title_full_unstemmed Sivelestat Attenuates Myocardial Reperfusion Injury during Brief Low Flow Postischemic Infusion
title_short Sivelestat Attenuates Myocardial Reperfusion Injury during Brief Low Flow Postischemic Infusion
title_sort sivelestat attenuates myocardial reperfusion injury during brief low flow postischemic infusion
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674745/
https://www.ncbi.nlm.nih.gov/pubmed/23766850
http://dx.doi.org/10.1155/2013/279847
work_keys_str_mv AT aunesverree sivelestatattenuatesmyocardialreperfusioninjuryduringbrieflowflowpostischemicinfusion
AT yehstevet sivelestatattenuatesmyocardialreperfusioninjuryduringbrieflowflowpostischemicinfusion
AT kuppusamyperiannan sivelestatattenuatesmyocardialreperfusioninjuryduringbrieflowflowpostischemicinfusion
AT kuppusamymlakshmi sivelestatattenuatesmyocardialreperfusioninjuryduringbrieflowflowpostischemicinfusion
AT khanmahmood sivelestatattenuatesmyocardialreperfusioninjuryduringbrieflowflowpostischemicinfusion
AT angelosmarkg sivelestatattenuatesmyocardialreperfusioninjuryduringbrieflowflowpostischemicinfusion